NR4A1 and breast cancer: Another trial testing CDK4/6i in the adjuvant setting is the MonarchE trial, which evaluated the addition of 2 years of adjuvant abemacicilb to standard ET in hormone receptor positive, HER2-negative early BC patients who were at high risk of relapse after surgery [20].